FindTrial
Sign In

comparision between Aprepitant and Dexamethasone For Preventing Postoperative Nausea And Vomiting In Breast Cancer Patients

Aprepitant Versus Dexamethasone For Preventing Postoperative Nausea And Vomiting In Breast Cancer Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/12/005333
Enrollment
160
Registered
2014-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: null- Patients scheduled for elective surgery of age 18yrs with breast cancer, ASA grade 1-3

Interventions

Intervention1: Aprepitant: Patients in group I will receive 80 mg oral Aprepitant 3 hours before induction of anesthesia Control Intervention1: Dexamethasone: Patients in group II will receive 8mg dex

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients scheduled for elective surgery of age >18yrs with breast cancer, ASA grade 1-3

Exclusion criteria

Exclusion criteria: patients who had a history of drug abuse, hypersensitivity reaction, nausea and received antiemetic before surgery within 24 hours, pregnancy, breastfeeding status

Design outcomes

Primary

MeasureTime frame
The primary efficacy variable will be episodes of nausea and or vomiting in the early and late postoperative period in first 24 hoursTimepoint: The primary efficacy variable will be episodes of nausea and or vomiting in the early and late postoperative period in first 24 hours—

Secondary

MeasureTime frame
The incidence of any adverse reaction to treatment in the two experimental groups will be recordedTimepoint: till discharge—

Countries

India

Contacts

Public ContactSACHIDANAND JEE BHARATI

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

SACHIDADR@YAHOO.CO.IN29575101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026